Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors

A. Madani, K. Kemmer, C. Sweeney, C. Corless, Thomas Ulbright, M. Heinrich, Lawrence Einhorn

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: The majority of patients with germ-cell tumors (GCTs) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of KIT and the epidermal growth factor receptor (EGFR) to determine their incidence in chemorefractory disease. Patients and methods: We retrospectively analyzed 23 patients with chemorefractory non-seminomatous GCTs (15 late relapse and eight transformed teratomas). None of these 23 patients were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of KIT and EGFR was performed on the most recently available specimen from a metastatic site. PCR amplimers of KIT exon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing. Results: KIT was expressed (≥10% of the tumor displaying membranous or cytoplasmic staining) in 11 of 23 GCT patients [48%; 95% confidence interval (CI) 26% to 68%]. There were no activating KIT mutations in the phosphoryltransferase domain (exon 17) in 21 patients analyzed. EGFR was expressed (1+ to 3+) in 15 of 23 GCT patients (65%; 95% CI 41% to 82%). Conclusions: KIT and EGFR are expressed in a significant proportion of refractory GCTs. The significance of these findings will be determined by ongoing clinical trials.

Original languageEnglish
Pages (from-to)873-880
Number of pages8
JournalAnnals of Oncology
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Epidermal Growth Factor Receptor
Germ Cell and Embryonal Neoplasms
Drug Therapy
Exons
Confidence Intervals
Mutation
Teratoma
Nonseminomatous germ cell tumor
High Pressure Liquid Chromatography
Clinical Trials
Staining and Labeling
Recurrence
Polymerase Chain Reaction
Incidence
Neoplasms

Keywords

  • c-Kit
  • EGFR
  • Germ-cell tumor
  • Refractory
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. / Madani, A.; Kemmer, K.; Sweeney, C.; Corless, C.; Ulbright, Thomas; Heinrich, M.; Einhorn, Lawrence.

In: Annals of Oncology, Vol. 14, No. 6, 01.06.2003, p. 873-880.

Research output: Contribution to journalArticle

@article{0c3a08393d394959a7d56ffd833378ff,
title = "Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors",
abstract = "Background: The majority of patients with germ-cell tumors (GCTs) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of KIT and the epidermal growth factor receptor (EGFR) to determine their incidence in chemorefractory disease. Patients and methods: We retrospectively analyzed 23 patients with chemorefractory non-seminomatous GCTs (15 late relapse and eight transformed teratomas). None of these 23 patients were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of KIT and EGFR was performed on the most recently available specimen from a metastatic site. PCR amplimers of KIT exon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing. Results: KIT was expressed (≥10{\%} of the tumor displaying membranous or cytoplasmic staining) in 11 of 23 GCT patients [48{\%}; 95{\%} confidence interval (CI) 26{\%} to 68{\%}]. There were no activating KIT mutations in the phosphoryltransferase domain (exon 17) in 21 patients analyzed. EGFR was expressed (1+ to 3+) in 15 of 23 GCT patients (65{\%}; 95{\%} CI 41{\%} to 82{\%}). Conclusions: KIT and EGFR are expressed in a significant proportion of refractory GCTs. The significance of these findings will be determined by ongoing clinical trials.",
keywords = "c-Kit, EGFR, Germ-cell tumor, Refractory, Testicular cancer",
author = "A. Madani and K. Kemmer and C. Sweeney and C. Corless and Thomas Ulbright and M. Heinrich and Lawrence Einhorn",
year = "2003",
month = "6",
day = "1",
doi = "10.1093/annonc/mdg244",
language = "English",
volume = "14",
pages = "873--880",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors

AU - Madani, A.

AU - Kemmer, K.

AU - Sweeney, C.

AU - Corless, C.

AU - Ulbright, Thomas

AU - Heinrich, M.

AU - Einhorn, Lawrence

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Background: The majority of patients with germ-cell tumors (GCTs) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of KIT and the epidermal growth factor receptor (EGFR) to determine their incidence in chemorefractory disease. Patients and methods: We retrospectively analyzed 23 patients with chemorefractory non-seminomatous GCTs (15 late relapse and eight transformed teratomas). None of these 23 patients were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of KIT and EGFR was performed on the most recently available specimen from a metastatic site. PCR amplimers of KIT exon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing. Results: KIT was expressed (≥10% of the tumor displaying membranous or cytoplasmic staining) in 11 of 23 GCT patients [48%; 95% confidence interval (CI) 26% to 68%]. There were no activating KIT mutations in the phosphoryltransferase domain (exon 17) in 21 patients analyzed. EGFR was expressed (1+ to 3+) in 15 of 23 GCT patients (65%; 95% CI 41% to 82%). Conclusions: KIT and EGFR are expressed in a significant proportion of refractory GCTs. The significance of these findings will be determined by ongoing clinical trials.

AB - Background: The majority of patients with germ-cell tumors (GCTs) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of KIT and the epidermal growth factor receptor (EGFR) to determine their incidence in chemorefractory disease. Patients and methods: We retrospectively analyzed 23 patients with chemorefractory non-seminomatous GCTs (15 late relapse and eight transformed teratomas). None of these 23 patients were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of KIT and EGFR was performed on the most recently available specimen from a metastatic site. PCR amplimers of KIT exon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing. Results: KIT was expressed (≥10% of the tumor displaying membranous or cytoplasmic staining) in 11 of 23 GCT patients [48%; 95% confidence interval (CI) 26% to 68%]. There were no activating KIT mutations in the phosphoryltransferase domain (exon 17) in 21 patients analyzed. EGFR was expressed (1+ to 3+) in 15 of 23 GCT patients (65%; 95% CI 41% to 82%). Conclusions: KIT and EGFR are expressed in a significant proportion of refractory GCTs. The significance of these findings will be determined by ongoing clinical trials.

KW - c-Kit

KW - EGFR

KW - Germ-cell tumor

KW - Refractory

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=0038012182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038012182&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg244

DO - 10.1093/annonc/mdg244

M3 - Article

VL - 14

SP - 873

EP - 880

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -